Patient group b
Erwachsene mit schubförmiger Multipler Sklerose (RMS) mit hochaktiver Erkrankung trotz Behandlung mit einer krankheitsmodifizierenden Therapie1.
Added benefit not proven
Comparator
- Alemtuzumab oder Fingolimod oder Natalizumab
final resolution2021-12-02active
Arzneimittel-Richtlinie/Anlage XII: Ponesimod (Schubförmige Multiple Sklerose), Patientengruppe b
Open official decision page ↗
G-BA source · retrieved 2026-08-05
Structured conclusion
Final result by patient group
1 source-verified result
Decision orientation
What the G-BA did
4 cited claims
Each claim links to the official G-BA page or an exact PDF page range.
Official metadata
- Decision date
- 2021-12-02
- Effective
- 02.12.2021
- Action type
- final resolution
- Committee
- Arzneimittel
Case context
Listed normative targets
directiveArzneimittel-Richtlinie
directive annexAnlage XII: Nutzenbewertung nach § 35a SGB V
A listed target is not treated as a new directive version unless an official version source exists.
Official document package